Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide For Obstructive Sleep Apnea Triumph Trial Results

Retatrutide for obstructive sleep apnea triumph trial results show promising early signs in Eli Lilly's Phase 3 TRIUMPH program[5], with preliminary data indicating substantial reductions in apnea-hypopnea index (AHI) scores[4] and significant weight loss[1]. These findings come from basket trials nested within weight management studies[4], highlighting retatrutide's potential as a triple agonist therapy for OSA linked to obesity. While full topline results for OSA endpoints are still pending[4], related outcomes from TRIUMPH-4 underscore its efficacy in body weight reduction and related conditions[1], building on Phase 2 evidence where weight loss correlated with AHI improvements[2].

What Is Retatrutide and Its Role in Treating Obstructive Sleep Apnea?

Retatrutide is an investigational drug developed to tackle obesity-related conditions like obstructive sleep apnea (OSA). It works by targeting multiple hormones to promote weight loss, which is key since excess weight often worsens OSA by narrowing airways during sleep. Losing even 10% of body weight can reduce AHI by about 26%[2], making retatrutide's strong weight loss profile relevant for OSA management[2].

Triple Agonist Mechanism: GIP, GLP-1, and Glucagon Activation

Retatrutide activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

This triple action helps control blood sugar, reduce appetite, and increase energy use, leading to greater weight loss than single or dual agonists. In OSA, this mechanism may ease breathing issues by shrinking fat around the neck and improving overall sleep quality[6].

Developer: Eli Lilly and Company

Eli Lilly and Company, a leader in diabetes and obesity drugs, is behind retatrutide. The company has a track record with GLP-1 drugs like tirzepatide (Mounjaro). Their TRIUMPH program tests retatrutide across obesity, OSA, and osteoarthritis[5].

Administration: Weekly Subcutaneous Injections with Diet and Exercise

Patients receive retatrutide as a once-weekly shot under the skin, starting low and increasing to doses like 12 mg[3]. It's paired with diet changes and exercise for best results. This simple routine fits well for long-term OSA management[3].

Overview of the TRIUMPH Phase 3 Clinical Trial Program

The TRIUMPH program is a set of large Phase 3 trials testing retatrutide against placebo in over 5,800 adults[4], aiming to deliver key retatrutide for obstructive sleep apnea triumph trial results alongside obesity data. It uses a smart "basket" design—studies that efficiently test the drug for multiple related conditions like obesity, OSA, and knee osteoarthritis by sharing groups of participants—to speed up development while controlling costs[4].

Program Design: Basket Trials for Obesity, OSA, and Knee Osteoarthritis

Basket trials nest specific studies, like OSA, inside main weight loss trials. This saves time and shares data across conditions driven by excess fat. The trials control for false positive results using a statistical threshold called alpha = 0.05[4] to ensure reliable stats[4].

Key Trials: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4

TRIUMPH-1 and -2 focus on weight management with OSA/OA nests.
TRIUMPH-3 targets heart disease risks in obesity.
TRIUMPH-4 stands alone for knee OA in overweight patients.

Each lasts up to 72 weeks[4], providing long-term data on sustained benefits.

Participant Details: Over 5,800 Enrolled, Type I Error Control (α=0.05)

Adults with BMI ≥30 (or ≥27 with issues) joined, many with OSA confirmed by sleep studies. Enrollment wrapped up by late 2025[5], including diverse groups to reflect real-world OSA patients.

Current Status: Ongoing with Enrollment Complete

Trials are in final stages, with TRIUMPH-4 topline out[1]. Full OSA data expected late 2026[1].

TRIUMPH-1 and TRIUMPH-2: OSA-Specific Baskets and Endpoints

TRIUMPH-1 and -2 embed OSA protocols in broader weight loss studies, making them efficient for generating retatrutide for obstructive sleep apnea triumph trial results[4].

Primary Endpoint: Change in Apnea-Hypopnea Index (AHI)

AHI measures breathing pauses per sleep hour—over 15 means moderate OSA, over 30 severe. The goal: big drops in AHI with retatrutide vs. placebo[4], measured via overnight sleep studies at baseline and follow-up.

Nested Protocols Within Weight Management Trials

OSA patients get the same drug but extra sleep monitoring. This directly links weight loss to apnea improvements, as fat reduction opens airways.

Trial Populations and Durations (Up to 72 Weeks)

Hundreds with moderate-to-severe OSA (AHI 15-100) per trial, plus obesity[4]. Follow-up hits 72 weeks to check if benefits last, crucial for chronic OSA.

Retatrutide for Obstructive Sleep Apnea Triumph Trial Results: Efficacy Data

Early retatrutide for obstructive sleep apnea triumph trial results point to strong potential via weight loss, though full Phase 3 OSA readouts await. Phase 2 data showed up to 24.2% weight loss over 48 weeks, with post-hoc analysis in obese patients linking this to AHI reductions (estimated 26% AHI drop per 10% body weight lost)[2]. retatrutide phase 2 results provide foundational evidence for TRIUMPH expectations.

Preliminary AHI Reductions: -25.3 Events/Hour

Some early reports note AHI drops around -25.3 events/hour[4] in high-dose groups, potentially from Phase 2 subgroups or initial TRIUMPH analyses—evidence is limited and unconfirmed in full Phase 3 toplines. This scale could transform severe OSA cases, but awaits verification.

Normalized AHI in 52% of Participants

Preliminary metrics suggest 52% achieved normal AHI (<15 events/hour), far better than placebo in similar studies[4]. Uncertainty remains until official data releases.

Improved Sleep Quality Scores in 71%

About 71% showed better sleep via patient-reported surveys like the Functional Outcomes of Sleep Questionnaire[4]. These align with weight loss benefits but need Phase 3 confirmation.

Weight Loss Connections: Insights from Phase 2 and TRIUMPH-4 (28.7%)

Phase 2 hit 24.2% loss[2]; TRIUMPH-4 topped 28.7% at 68 weeks (26.6% adjusted)[1], exceeding forecasts. For OSA, such loss could normalize breathing in many, per established correlations[1].

Safety Data and Side Effects from TRIUMPH Trials

Safety in retatrutide for obstructive sleep apnea triumph trial results mirrors other weight loss drugs, with GI issues leading but mostly mild. Full OSA safety data is pending, but TRIUMPH-4 provides key insights across 5,800+ participants[1].

Common Adverse Events: Gastrointestinal Issues

Nausea, diarrhea, vomiting, and constipation hit more on retatrutide, easing over time. Dose ramp-up helps.

Rates: 40-60% mild/moderate.
Most stop by week 20.
Similar to tirzepatide or semaglutide profiles[4].

New Signal: Dysesthesia in Up to 20.9% at 12 mg Dose

Dysesthesia—an unusual skin sensation like tingling, burning, or numbness—affects up to 20.9% at high doses, but mostly mild with few dropouts (low impact on completion rates)[1]. retatrutide dysesthesia side effects explained in detail elsewhere.

Dropouts match placebo overall (around 10-15%); higher in low-BMI folks from side effects[1]. No major red flags for OSA subgroups yet.

OSA-Specific Safety: Pending Full Readouts

Sleep apnea patients monitored closely for breathing or heart issues, but data limited till 2026[1]. dysesthesia impact on retatrutide approval.

TRIUMPH-4 Results: Weight Loss and Knee OA Insights Relevant to OSA

Though not OSA-focused, TRIUMPH-4 data supports retatrutide's power for obesity-driven issues like apnea, as knee OA often co-occurs with OSA in overweight patients[1].

28.7% Mean Body Weight Loss (26.6% Placebo-Adjusted)

At 12 mg over 68 weeks, patients lost 28.7% weight—best yet for these drugs, vs. 20-23% prior estimates[1]. This level likely boosts OSA hugely via fat reduction.

WOMAC Pain Reduction: 75-76% Improvement

Knee pain fell 76% (4.5-point drop on 0-10 scale from baseline ~6); 12% pain-free vs. 4% placebo[1]. Better mobility aids exercise, indirectly helping OSA.

Additional Benefits: CV Risk, Blood Pressure, and Physical Function

Cuts in heart risks (e.g., lipids), blood pressure, and better function round it out[1]. Ties to OSA perks like less nighttime strain and daytime fatigue.

Legal Status, FDA Approval Timeline, and Availability

is retatrutide FDA approved? No—it's investigational only, including for retatrutide for obstructive sleep apnea triumph trial results[5].

Current Status: Investigational, Not FDA-Approved

Restricted to trials; no home use[5]. retatrutide FDA approval status for trackers.

NDA Submission: Expected Late 2026–Q2 2027

Post all data, Lilly plans filing then, pooling TRIUMPH evidence[5].

Projected Approval: Late 2027–2028 with Priority Review Potential

6-12 month review; priority if standout vs. competitors[5]. Launch 2028 possible.

Access: Restricted to Clinical Trials Only

Join via [3]. No compassionate use yet[3]. retatrutide release date and availability.

Future Implications and What to Watch For in OSA Treatment

Retatrutide for obstructive sleep apnea triumph trial results could transform care, potentially offering a pill-free alternative to CPAP machines for many.

Potential First Drug with FDA OSA Indication

If AHI data confirms Phase 2 trends[2], first label for apnea via weight loss mechanism.

Comparisons to Semaglutide and Tirzepatide

retatrutide vs semaglutide shows superior loss. Here's a quick comparison:

Drug	Max Weight Loss (Phase 3)	OSA AHI Impact (Est.)	Notes
Retatrutide	28.7% (TRIUMPH-4)[1]	-25%+ per reports	Triple agonist
Semaglutide	15-20% (STEP trials)	~20-26% per 10% loss	GLP-1 only
Tirzepatide	20-22% (SURMOUNT)	Similar correlation	Dual agonist

Retatrutide leads in potency for obesity-linked OSA[1].

Limitations: No Full OSA Topline Results Yet

Data mostly from TRIUMPH-4[1]; OSA metrics preliminary and unverified[4]. Basket design strong but not OSA-exclusive.

Next Steps: Full Data Readouts Expected Late 2026

Watch conferences like ADA or ATS 2026 for updates.

Conclusion: Promising but Pending Retatrutide Triumph Trial Results for OSA

Retatrutide for obstructive sleep apnea triumph trial results offer hope with potential AHI cuts and massive weight loss, but await full confirmation amid limited evidence. Safety looks manageable despite dysesthesia notes[1]. Stay tuned for 2026 data shaping OSA therapy.